133 related articles for article (PubMed ID: 7784270)
21. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Hussain M; Petrylak D; Fisher E; Tangen C; Crawford D
Semin Oncol; 1999 Oct; 26(5 Suppl 17):55-60. PubMed ID: 10604271
[TBL] [Abstract][Full Text] [Related]
24. Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination.
Athanasiadis A; Tsavdaridis D; Rigatos SK; Athanasiadis I; Pergantas N; Stathopoulos GP
Anticancer Res; 2003; 23(3C):3085-8. PubMed ID: 12926166
[TBL] [Abstract][Full Text] [Related]
25. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
[TBL] [Abstract][Full Text] [Related]
26. Estramustine-based chemotherapy.
Hudes G
Semin Urol Oncol; 1997 Feb; 15(1):13-9. PubMed ID: 9050135
[TBL] [Abstract][Full Text] [Related]
27. Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Sleijfer S; Stoter G
Nat Clin Pract Oncol; 2005 Feb; 2(2):70-1. PubMed ID: 16264874
[No Abstract] [Full Text] [Related]
28. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
Arah IN; Dixon SC; Horti J; Figg WD
Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
[TBL] [Abstract][Full Text] [Related]
29. Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients.
Takenaka A; Yamada Y; Kurahashi T; Soga H; Miyake H; Fujisawa M
Int J Urol; 2008 Jan; 15(1):106-9. PubMed ID: 18184188
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Getzenberg RH; Light BW; Lapco PE; Konety BR; Nangia AK; Acierno JS; Dhir R; Shurin Z; Day RS; Trump DL; Johnson CS
Urology; 1997 Dec; 50(6):999-1006. PubMed ID: 9426741
[TBL] [Abstract][Full Text] [Related]
31. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
[TBL] [Abstract][Full Text] [Related]
32. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer.
Hudes GR; Greenberg R; Krigel RL; Fox S; Scher R; Litwin S; Watts P; Speicher L; Tew K; Comis R
J Clin Oncol; 1992 Nov; 10(11):1754-61. PubMed ID: 1383436
[TBL] [Abstract][Full Text] [Related]
33. Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.
Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;
Urol Oncol; 2005; 23(1):1-7. PubMed ID: 15885575
[TBL] [Abstract][Full Text] [Related]
34. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer.
Naik HR; Lehr JE; Pienta KJ
Anticancer Res; 1994; 14(6B):2617-9. PubMed ID: 7872690
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
Berry W; Friedland D; Fleagle J; Jackson D; Ilegbodu D; Boehm KA; Asmar L
Clin Genitourin Cancer; 2006 Sep; 5(2):131-7. PubMed ID: 17026801
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
[TBL] [Abstract][Full Text] [Related]
37. Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Sinibaldi VJ; Carducci M; Laufer M; Eisenberger M
Semin Oncol; 1999 Oct; 26(5 Suppl 17):45-8. PubMed ID: 10604269
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Petrylak DP; Tangen CM; Hussain MH; Lara PN; Jones JA; Taplin ME; Burch PA; Berry D; Moinpour C; Kohli M; Benson MC; Small EJ; Raghavan D; Crawford ED
N Engl J Med; 2004 Oct; 351(15):1513-20. PubMed ID: 15470214
[TBL] [Abstract][Full Text] [Related]
39. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Haas N; Roth B; Garay C; Yeslow G; Entmacher M; Weinstein A; Rogatko A; Babb J; Minnitti C; Flinker D; Gillon T; Hudes G
Urology; 2001 Jul; 58(1):59-64. PubMed ID: 11445480
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Hudes GR; Nathan FE; Khater C; Greenberg R; Gomella L; Stern C; McAleer C
Semin Oncol; 1995 Oct; 22(5 Suppl 12):41-5. PubMed ID: 7481860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
